PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
40635637,Innate and Adaptive Immune Responses to Clinical Hyaluronic Acid Fillers.,2025-Jul,,,
40635616,HER2-Targeted Nanoliposome Therapy Activates Immune Response by Converting Cold to Hot Breast Tumors.,2025,,,
40630742,Cytokine Release Syndrome Induced by Pembrolizumab for Metastatic Anal Melanoma.,2025,,,
40630125,Adverse event profile of five anti head and neck squamous cell carcinoma drugs: a descriptive analysis from WHO-VigiAccess.,2025,,,
40629658,Immune infiltration and drug treatment response of angiogenesis-related LncRNA in lung adenocarcinoma.,2025-Jul-04,,,
40629032,Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective.,2025-Jul-08,,,Leili_aghebati_maleki@yahoo.com.
40627401,Controlling T cell-tumor cell interaction with a biomimetic physical barrier for cancer immunotherapy.,2025-Jul-15,Zhang; Wang; Qing; Wang; Li; Luo; Wang; Liu; Wang; Ni; Li; Chen; Li; Liang,"Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.; Laboratory of Controllable Nanopharmaceuticals, Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China.",
40626119,Metronomic chemotherapy in pediatric neuroblastoma.,2024-Dec,,,
40626006,Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure.,2025,,,
40624659,One step further in targeting acute leukemia by combining antibody-based immunotherapies and small molecule inhibitors.,2025-Jul-07,,,s.taghilo@mazums.ac.ir.
40624367,"EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma.",2025-Jul-07,,,eterpos@med.uoa.gr.
40623766,The multipotential effect of microbiome in lung cancer development and progression.,2025,,,smoghadd@mdanderson.org.
40619808,Rescued with T and B lymphocytes depletion therapy for immune checkpoint inhibitor-associated transplant rejection.,2025-Jul-06,,,
40619486,Cytotoxic Anti-tumor Drugs and Tumor-Associated Macrophages Synergistically Surge PD-L1 Expression in Esophageal Squamous Cell Carcinoma.,2025-Jul-06,,,mimori.koshi.791@m.kyushu-u.ac.jp.
40618968,Nanocarrier-driven neutron capture therapy: Strategies and perspectives.,2025-Jul-04,,,lijie@xzhmu.edu.cn.
40618853,Optimized bacterial delivery approaches for precision immunotherapy in breast cancer models.,2025-Jul-04,,,jisunkim@kribb.re.kr.
40618676,Dose optimization in cancer drug development: Review and outcome of a multi-stakeholder workshop.,2025-Jun-28,Glasmacher; Li,"Cancer Drug Development Forum (CDDF) asbl, Brussels Life Science Incubator, Clos Chapelle-aux-Champs 30, Bt 1.30.30, 1200 Woluwe Saint Lambert, Belgium; Dep. of Internal Medicine III, Universit√§tsklinikum Bonn, Venusberg-Campus 1, Bonn 53127, Germany. Electronic address: glasmacher@uni-bonn.de.; Department of Clinical Pharmacology, Genentech, Inc, South San Francisco, CA, USA.",glasmacher@uni-bonn.de.
40617070,"Clinical Profile, Intensive Care Needs, and Short-Term Outcome of Acute Necrotizing Encephalopathy of Childhood: A Retrospective Study From a Tertiary Care Hospital in North India.",2025-Jun-20,,,drarunbansal@gmail.com.
40617046,Toward immune tolerance in rheumatoid arthritis: Emerging immunotherapies and targets for long-term remission.,2025-Jul-04,,,khorramdelazad@gmail.com.
40615690,Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer.,2025-Jul-04,,,Priya.Jayachandran@med.usc.edu.
